High-Dose Calcitriol, Zoledronate, and Dexamethasone for the Treatment of Progressive Prostate Carcinoma Academic Article uri icon

Overview

MeSH Major

  • Calcitriol
  • Carcinoma
  • Dexamethasone
  • Diphosphonates
  • Imidazoles
  • Prostatic Neoplasms

abstract

  • Calcitriol was well tolerated at doses up to and including 30 microg 3 times per week in combination with intravenous zoledronate 4 mg monthly, with or without dexamethasone, in patients with progressive prostate carcinoma. Peak plasma levels in the 24 microg and 30 microg cohorts were greater than the levels associated with antitumor effects preclinically. Due to the cumbersome dosing schedule and the lack of significant activity observed, Phase II trials of this regimen are not planned.

publication date

  • May 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.20185

PubMed ID

  • 15112267

Additional Document Info

start page

  • 1868

end page

  • 75

volume

  • 100

number

  • 9